

21 March 2022

Kiwi Angel

By email: fyi-request-18804-be9231e2@requests.fyi.org.nz
Ref: H202203698

Tēnā koe

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of Health (the Ministry) on 7 March 2022 for information about the Pfizer COVID-19 Comirnaty vaccine. Specifically, you asked:

"I would like information and correspondence in regards to the Pfizer papers released last week reporting on the results of serious Adverse Events Data and deaths from mRNA vaccine. There are 9 pages of side-effects, long term damage and death. 1,223 deaths fatalities during a three month period and 42,000 reported adverse events. This data shows a 3% fatality rate which is seen as extremely high in terms of vaccine efficacy. As a concerned mother I would like a copy of any correspondence the MOH has relating to these Pfizer Papers. Also papers & correspondence relating to the latest research out of Sweden on Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line."

The Ministry has interpreted your request for information about "the Pfizer papers" to be about the *Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021* (hereafter the Cumulative Analysis Report) that was published in the United States last year. The Ministry received numerous requests about the genesis of the Cumulative Analysis Report and has published responses to three of them on its website. They are available under the 12 January 2022 publication date for *Information on Pfizer Cumulative Analysis Report* at: www.health.govt.nz/about-ministry/information-releases/responses-official-information-act-requests. Your request is therefore refused under section 18(d) of the Act on the grounds that the information sought is publicly available.

Regarding your request for information about research conducted in Sweden, the Ministry's COVID-19 Science and Technical Advisory Group advises that the study was flawed by its use of a liver cancer cell line that bears little resemblance to normal healthy human cells. While the Ministry will continue to monitor information on this issue, it advises that to date no researchers have been able to provide robust genomic evidence of reverse transcription of RNA and DNA integration into human genomes.

Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Please note that this response, with your personal details removed, may be published on the Ministry website at: www.health.govt.nz/about-ministry/information-releases/responses-official-information-act-requests.

Nāku noa, nā



Jan Torres
Acting Manager, OIA Services
Office of the Director-General